Dupixent to be reviewed by DREC for reimb after 2 years
By Eo, Yun-Ho | translator Kang, Shin-Kook
23.01.12 06:00:10
가나다라
0
Will be discussed at HIRA today...whether the reimbursement extension will be approved gains attention
Applied for reimb in April 2021... took 1 year to set reimbursement standards
According to industry sources, the low-dose formulation (200mg) of Sanofi-Aventis Korea’s Dupixent (dupilumab) will be deliberated by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee today on the 12th. This progress has been made 2 years after the company applied for the reimbursement extension in April 2021.
It first took 7 months for expert opinion inquiries to begin on extending reimbursement of Dupixent to pediatric and adolescent patients, and the reimbursement standards for the indication were set in May last yea
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)